Ghrelin Is No Longer Able to Stimulate Growth Hormone Secretion in Patients with Cushing’s Syndrome but Instead Induces Exaggerated Corticotropin and Cortisol Responses
暂无分享,去创建一个
F. Casanueva | E. Arvat | E. Ghigo | C. Diéguez | R. Deghenghi | A. Leal-Cerro | E. Torres | A. Soto | Elena Dios | A. Leal‐Cerro
[1] F. Casanueva,et al. Ghrelin: The Link Connecting Growth with Metabolism and Energy Homeostasis , 2002, Reviews in Endocrine and Metabolic Disorders.
[2] M. Papotti,et al. The GH‐releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans , 2002, Clinical endocrinology.
[3] K. Hosoda,et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. , 2001, The Journal of clinical endocrinology and metabolism.
[4] B. Wisse,et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. , 2001, Diabetes.
[5] M. Tschöp,et al. Post-prandial decrease of circulating human ghrelin levels , 2001, Journal of endocrinological investigation.
[6] M. Papotti,et al. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. , 2001, The Journal of clinical endocrinology and metabolism.
[7] K. Toshinai,et al. Upregulation of Ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. , 2001, Biochemical and biophysical research communications.
[8] M. Papotti,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Endocrine Activities of Ghrelin, a Natural Growth Hormone Secretagogue (GHS), in Humans: Comparison and Interactions with Hexarelin, a Nonnatura , 2022 .
[9] K. Nakao,et al. Ghrelin strongly stimulates growth hormone release in humans. , 2000, The Journal of clinical endocrinology and metabolism.
[10] F. Casanueva,et al. Ghrelin-induced growth hormone secretion in humans. , 2000, European journal of endocrinology.
[11] R. Pasquali,et al. Abnormalities of the hypothalamic-pituitary-adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and a peripheral alteration. , 2000, The Journal of clinical endocrinology and metabolism.
[12] S. Dickson,et al. Systemic Administration of Ghrelin Induces Fos and Egr‐1 Proteins in the Hypothalamic Arcuate Nucleus of Fasted and Fed Rats , 2000, Journal of neuroendocrinology.
[13] F. Casanueva,et al. Ghrelin elicits a marked stimulatory effect on GH secretion in freely-moving rats. , 2000, European journal of endocrinology.
[14] M. Papotti,et al. Growth hormone secretagogue binding sites in peripheral human tissues. , 2000, The Journal of clinical endocrinology and metabolism.
[15] F. Casanueva,et al. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults , 2000, The Lancet.
[16] M. Papotti,et al. Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans , 2000, Journal of endocrinological investigation.
[17] M. Nakazato,et al. Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. , 2000, Biochemical and biophysical research communications.
[18] F. Casanueva,et al. Ghrelin: a step forward in the understanding of somatotroph cell function and growth regulation. , 2000, European journal of endocrinology.
[19] M. Nakazato,et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.
[20] M. Korbonits,et al. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. , 1999, The Journal of clinical endocrinology and metabolism.
[21] F. Casanueva,et al. Growth Hormone Secretagogues: Physiological Role and Clinical Utility , 1999, Trends in Endocrinology & Metabolism.
[22] J. Veldhuis,et al. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. , 1998, Endocrine reviews.
[23] G. Arnaldi,et al. Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma. , 1998, The Journal of clinical endocrinology and metabolism.
[24] F. Casanueva,et al. Interaction between body composition, leptin and growth hormone status. , 1998, Bailliere's clinical endocrinology and metabolism.
[25] D. Schoenfeld,et al. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. , 1998, The Journal of clinical endocrinology and metabolism.
[26] M. Buysschaert,et al. Cushing's disease: a comparison of pituitary corticotroph microadenomas and macroadenomas. , 1998, European journal of endocrinology.
[27] Jimenez,et al. Enhanced growth hormone (GH) responsiveness to GH‐releasing hormone after dietary restriction in patients with Cushing's syndrome , 1998, Clinical endocrinology.
[28] X. Bertagna,et al. Widespread transcription of the growth hormone-releasing peptide receptor gene in neuroendocrine human tumors. , 1997, European journal of endocrinology.
[29] F. Casanueva,et al. Acute pharmacological reduction of plasma free fatty acids enhances the growth hormone (GH)-releasing hormone-mediated GH secretion in patients with Cushing's syndrome. , 1997, The Journal of clinical endocrinology and metabolism.
[30] E. Arvat,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Adrenocorticotropin- and Cortisol-Releasing Effect of Hexarelin, a Synthetic Growth Hormone-Releasing , 2022 .
[31] T. Yoshimoto,et al. Clinico‐pathological study of Cushing's disease with large pituitary adenoma , 1997, Clinical endocrinology.
[32] H. Orskov,et al. Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. , 1997, The American journal of physiology.
[33] I. Robinson,et al. Printed in U.S.A. Copyright © 1997 by The Endocrine Society Activation of the Hypothalamo-Pituitary-Adrenal Axis by the Growth Hormone (GH) Secretagogue, GH-Releasing Peptide-6, in Rats , 2022 .
[34] Patrick R. Griffin,et al. A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release , 1996, Science.
[35] R. Mcdowell,et al. In vitro characterization of four novel classes of growth hormone-releasing peptide. , 1995, Endocrinology.
[36] B. Imbimbo,et al. Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess. , 1995, The Journal of endocrinology.
[37] F. Casanueva,et al. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. , 1995, The Journal of clinical endocrinology and metabolism.
[38] F. Casanueva,et al. Influence of metabolic substrates and obesity on growth hormone secretion , 1995, Trends in Endocrinology & Metabolism.
[39] H. de Boer,et al. Clinical aspects of growth hormone deficiency in adults. , 1995, Endocrine reviews.
[40] F. Casanueva,et al. Inhibition of growth hormone release after the combined administration of CHRH and GHRP‐6 in patients with Cushing's syndrome , 1994, Clinical endocrinology.
[41] F. Casanueva,et al. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. , 1993, The Journal of clinical endocrinology and metabolism.
[42] F. Casanueva,et al. Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome , 1993, Clinical endocrinology.
[43] F. Cordido,et al. EFFECT OF ENHANCEMENT OF ENDOGENOUS CHOLINERGIC TONE WITH PYRIDOSTIGMINE ON GROWTH HORMONE (GH) RESPONSES TO GH‐RELEASING HORMONE IN PATIENTS WITH CUSHING'S SYNDROME , 1990, Clinical endocrinology.
[44] P. Sönksen,et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. , 1989, The New England journal of medicine.
[45] N. Skakkebaek,et al. BENEFICIAL EFFECTS OF GROWTH HORMONE TREATMENT IN GH-DEFICIENT ADULTS , 1989, The Lancet.
[46] T. Benraad,et al. HUMAN PANCREATIC GROWTH HORMONE RELEASING HORMONE FAILS TO STIMULATE HUMAN GROWTH HORMONE BOTH IN CUSHING'S DISEASE AND IN CUSHING'S SYNDROME DUE TO ADRENOCORTICAL ADENOMA , 1986, Clinical endocrinology.
[47] F. Momany,et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. , 1984, Endocrinology.
[48] H. Demura,et al. Responses of plasma ACTH, GH, LH and 11-hydroxycorticosteroids to various stimuli in patients with Cushing's syndrome. , 1972, The Journal of clinical endocrinology and metabolism.
[49] G. Chrousos,et al. Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical cure. , 1994, The Journal of clinical endocrinology and metabolism.
[50] A. Iranmanesh,et al. Divergent effects of short term glucocorticoid excess on the gonadotropic and somatotropic axes in normal men. , 1992, The Journal of clinical endocrinology and metabolism.
[51] B. Burguera,et al. Acute administration of corticoids: a new and peculiar stimulus of growth hormone secretion in man. , 1990, The Journal of clinical endocrinology and metabolism.